Comparison of Standard Opioid Prescription Versus Prescription Guided by Pharmacogenetic Analysis in Patients With Non-cancerous Chronic Pain.
NCT ID: NCT03498014
Last Updated: 2023-02-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2022-07-31
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Non-interventional, Observational Study for Quality of Life (Overall Health Assessment) in Patients With Chronic Severe Pain During Targinact® Treatment
NCT01710917
A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Chronic Pain Trial)
NCT05966142
Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain.
NCT05905146
Variation in Opioid Prescribing and Use for Acute Pain in Diverse Populations
NCT04509115
A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Acute Pain Trial)
NCT05966129
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prescription as standard
Standard opioid prescription
Opioid prescription made without reference to patient genetic profile (tramadol, codeine or oxycodone)
Pharmacogenetic-guided prescription
Pharmacogenetic analysis allowing personalized opioid prescription
Genotypic of patient to determine optimal opioid treatment (tramadol, codeine or oxycodone)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pharmacogenetic analysis allowing personalized opioid prescription
Genotypic of patient to determine optimal opioid treatment (tramadol, codeine or oxycodone)
Standard opioid prescription
Opioid prescription made without reference to patient genetic profile (tramadol, codeine or oxycodone)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient must be a member or beneficiary of a health insurance plan
* The patient is at least 18 years old
* The patient will be available for all visits
* Patients suffer from non-cancerous chronic pain according to HAS criteria
* Patient not having taking opioids in previous 2 months
* Patient indicated for prescription of opioids (oxycodone, codeine or tramadol) or patient not responding to first line treatment
Exclusion Criteria
* The subject refuses to sign the consent
* It is impossible to give the subject informed information
* The patient is under safeguard of justice or state guardianship
* The patient is pregnant or breastfeeding
* The patient is likely to procreate and does not use an effective method of contraception (contraceptive ring, surgical contraception, implant, patch, contraceptive pill, male and female condoms, IUD)
* There is a contra-indication for opioid use
* Patient with an addiction risk (score ≥ 8 on ORT scale).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nīmes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Christophe Boyer
Role: PRINCIPAL_INVESTIGATOR
CHU Nimes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Nimes
Nîmes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIMAO/2017-02/JCB-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.